$123.47
-0.03 (-0.02%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where INCY is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
265 interventional · 7 observational · 10 expanded access · 125 with posted results
Held by 18 tracked-famous managers (Dodge & Cox, AQR CAPITAL MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, TWO SIGMA INVESTMENTS, LP, MARSHALL WACE, LLP, +13 more) · FINRA short interest 4.8 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 2 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control PopulationNCT06259669observationalNumber of major congenital malformation (MCM)s | — | Recruiting | Drug: Ruxolitinib Cream | Pregnancy Related, Atopic Dermatitis | 958 | 2032-08-01 | in 2,174 d | 2025-12-11 |
| A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)NCT06615050GVHD-free survival (GFS)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Tacrolimus (Tac), Methotrexate (MTX), Ruxolitinib (Rux), Cyclophosphamide, Mycophenolate mofetil (MMF) | Graft-versus-host Disease (GVHD) | 572 | 2031-01-17 | in 1,612 d | 2026-05-20 |
| Study of INCA036978 in Participants With Myeloproliferative NeoplasmsNCT07441694Number of participants with Dose Limiting Toxicities (DLT)s in Part 1Randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: INCA036978, Standard disease-directed therapy | Myeloproliferative Neoplasms | 218 | 2030-05-24 | in 1,374 d | 2026-07-22 |
| A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential ThrombocythemiaNCT07623200Durable clinicohematologic response (DCR)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: INCA033989, Best Available Treatment | Essential Thrombocythemia | 426 | 2029-06-15 | in 1,031 d | 2026-08-06 |
| A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsNCT05836324Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: INCA33890, bevacizumab, FOLFIRI, FOLFOX, Cetuximab, ADG126 | Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors | 570 | 2029-05-03 | in 988 d | 2026-07-23 |
| A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)NCT07124078Objective Response (OR) at 6 monthsRandomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: INCA034176, Best available Treatment (BAT) | Chronic Graft-versus-host-disease | 60 | 2029-01-31 | in 896 d | 2026-06-02 |
| A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal CancerNCT07284849Progression-Free Survival (PFS)Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: INCA33890, Placebo, Bevacizumab, FOLFOX | CRC (Colorectal Cancer) | 700 | 2028-12-29 | in 863 d | 2026-08-06 |
| Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionNCT07214779Progression-Free Survival (PFS) by BICRRandomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: INCB123667, Investigator's choice of chemotherapy | Ovarian Cancer | 466 | 2028-11-15 | in 819 d | 2026-08-06 |
| A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsNCT06034002Number of participants with Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: INCA033989, Ruxolitinib | Myeloproliferative Neoplasms | 290 | 2028-10-29 | in 802 d | 2026-04-17 |
| A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative NeoplasmsNCT06313593Number of participants with Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: INCB160058, Standard disease-directed therapy | Myeloproliferative Neoplasms | 37 | 2028-10-09 | in 782 d | 2026-08-12 |
| A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal AdenocarcinomaNCT07522073Overall Survival (OS)Randomized · Double-masked · Treatment | Phase 3 | Recruiting | Drug: INCB161734, Placebo, Investigator's choice of chemotherapy | Solid Tumors | 588 | 2028-09-15 | in 758 d | 2026-08-06 |
| A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological MalignanciesNCT07195916Part 1A : Occurrence of Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: INCA036873 | Solid Tumors, Hematologic Malignancies | 280 | 2028-08-18 | in 730 d | 2026-08-06 |
| A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic TherapyNCT06821542Objective Response (OR) at 6 monthsRandomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: INCA034176, Best Available Therapy (BAT) | Chronic Graft-versus-host-disease | 9 | 2028-05-31 | in 651 d | 2026-03-23 |
| Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis SuppurativaNCT07213973Proportion of participants with Treatment-Emergent Adverse Events (TEAEs)Non-randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Povorcitinib | Hidradenitis Suppurativa (HS) | 40 | 2028-03-25 | in 584 d | 2026-08-06 |
| A Study to Evaluate INCA035784 in Participants With Myeloproliferative NeoplasmsNCT07008118Number of participants with Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: INCA035784 | Myeloproliferative Neoplasms | 120 | 2028-03-14 | in 573 d | 2026-08-06 |
| A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsNCT05936359Number of participants with Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: INCA033989, Ruxolitinib | Myeloproliferative Neoplasms | 160 | 2028-02-29 | in 559 d | 2026-08-10 |
| Rollover Study for Participants Previously Enrolled in Clinical Trials of PovorcitinibNCT06855498Proportion of participants with Treatment-Emergent Adverse Events (TEAEs)Open-label · Treatment | Phase 3 | Recruiting | Drug: povorcitinib | Hidradenitis Suppurativa (HS) | 600 | 2028-02-28 | in 558 d | 2026-08-06 |
| Observational Study for Patients at Risk for Chronic Graft-Versus-Host DiseaseNCT05919511observationalOverall Burden of cGVHD diagnosis and severity | — | Recruiting | Other: Non-Interventional | cGVHD | 1,500 | 2027-10-15 | in 422 d | 2026-03-24 |
| An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of RuxolitinibNCT02955940Frequency and types of adverse events and serious adverse eventsNon-randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Ruxolitinib, Capecitabine, Regorafenib | Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung Cancer | 10 | 2027-09-30 | in 407 d | 2026-08-17 |
| A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host DiseaseNCT06585774Event Free Survival (EFS)Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: INCA034176, Placebo, Corticosteroids | Chronic Graft-versus-host-disease | 240 | 2027-09-28 | in 405 d | 2026-08-06 |
| Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell DisordersNCT07104565Number of participants with Treatment-emergent Adverse Events (TEAEs)Non-randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: INCA000585 | Immune Thrombocytopenia | 56 | 2027-09-23 | in 400 d | 2026-08-06 |
| Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With TafasitamabNCT06465433Number of participants with Treatment-emergent Adverse Events (TEAEs)Open-label · Treatment | Phase 2 | Recruiting | Drug: Tafasitamab | Hematologic Malignancies | 25 | 2027-08-29 | in 375 d | 2025-12-10 |
| An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database AnalysisNCT06627335observationalNumber of major congenital malformation (MCM)s | — | Recruiting | Drug: Ruxolitinib Cream, TCS | Pregnancy Related, Atopic Dermatitis | 5,621 | 2027-08-15 | in 361 d | 2025-12-11 |
| To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans ProgressivaNCT05090891Double Blind Period: Occurrence of new heterotopic ossification (HO) lesions from baselineRandomized · Double-masked · Treatment | Phase 2 | Recruiting | Drug: INCB000928, Placebo | Fibrodysplasia Ossificans Progressiva (FOP) | 98 | 2027-07-30 | in 345 d | 2026-05-22 |
| Study of INCB123667 in Subjects With Advanced Solid TumorsNCT05238922Part 1A : Occurrence of Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: INCB0123667, Palbociclib, Bevacizumab, Olaparib, Paclitaxel, Ribociclib, Fulvestrant | Solid Tumors | 291 | 2027-07-27 | in 342 d | 2026-07-21 |
| A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host DiseaseNCT06388564Objective Response RateRandomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Axatilimab, Ruxolitinib, Corticosteroids | Chronic Graft-versus-host-disease | 130 | 2027-06-01 | in 286 d | 2026-05-22 |
| Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid NeoplasmsNCT04279847Number of treatment-emergent adverse eventsNon-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: INCB057643, Ruxolitinib | Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm, Relapsed or Refractory Primary Myelofibrosis, Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis), ET (Essential Thrombocythemia) | 140 | 2027-04-30 | in 254 d | 2026-04-01 |
| A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental VitiligoNCT06804811Proportion of Participants Achieving a ≥ 75% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI75)Randomized · Triple-masked · Treatment | Phase 3 | Recruiting | Drug: Ruxolitinib Cream, Vehicle Cream | NonSegmental Vitiligo | 250 | 2027-04-30 | in 254 d | 2026-07-22 |
| A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionNCT07023627Objective Response by IRCNon-randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: INCB123667 | Ovarian Cancer | 160 | 2027-04-27 | in 251 d | 2026-08-06 |
| A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic ImpairmentNCT07559474PK for plasma INCB123667: CmaxRandomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: INCB123667 | Hepatic Insufficiency, Liver Diseases | 16 | 2027-04-13 | in 237 d | 2026-06-16 |
| A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D MutationNCT06818812Number of participants with Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: INCB186748, Cetuximab, GEMNabP, mFOLFIRINOX | Solid Tumors | 30 | 2027-03-27 | in 220 d | 2026-03-23 |
| A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHDNCT06843408Number of participants with Treatment-emergent Adverse Events (TEAEs)Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: INCA034176 | Chronic Graft-versus-host-disease | 32 | 2027-01-06 | in 140 d | 2026-08-10 |
| A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal DiseaseNCT07559396PK for plasma INCB123667: CmaxRandomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: INCB123667 | Renal Impairment | 16 | 2027-01-04 | in 138 d | 2026-06-16 |
| A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D MutationNCT06179160Number of participants with Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: INCB161734, Cetuximab, Retifanlimab, GEMNabP, mFOLFIRINOX, FOLFOX, FOLFIRI, INCA33890 | Solid Tumors | 710 | 2027-01-01 | in 135 d | 2026-07-22 |
| A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis SuppurativaNCT06212999Proportion of participants with Treatment-Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Povorcitinib | Hidradenitis Suppurativa (HS) | 617 | 2026-12-26 | in 129 d | 2026-03-23 |
| Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis SuppurativaNCT07049575Number of participants with Treatment-emergent Adverse Events (TEAEs)Open-label · Treatment | Phase 1 | Recruiting | Drug: Ruxolitinib Cream | Hidradenitis Suppurativa | 24 | 2026-12-09 | in 112 d | 2026-08-06 |
| A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe AsthmaNCT05851443Absolute change in pre-bronchodilator forced expiratory volume in the first 1 second (pre-BD FEV1)Randomized · Double-masked · Treatment | Phase 2 | Active, not recruiting | Drug: povorcitinib, ICS-LABA · Other: placebo | Moderate to Severe Asthma | 247 | 2026-11-20 | in 93 d | 2026-07-07 |
| Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)NCT04509700Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Non-randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Parsaclisib, parsaclisib + itacitinib, parsaclisib + ruxolitinib, parsaclisib + ibrutinib | B-Cell Malignancies | 112 | 2026-11-05 | in 78 d | 2026-06-25 |
| A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)NCT06516952Proportion of participants achieving Itch NRS4 and IGA-CPG-S-TS at Week 24Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Povorcitinib, Placebo | Prurigo Nodularis | 349 | 2026-10-19 | in 61 d | 2026-05-28 |
| A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)NCT06516965Proportion of participants achieving Itch NRS4 and IGA-CPG-S-TS at Week 24Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Povorcitinib, Placebo | Prurigo Nodularis | 346 | 2026-10-19 | in 61 d | 2026-04-14 |
| A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult ParticipantsNCT07448155Pharmacokinetics Parameter: Cmax of INCA33989 following a single SC administration compared with a single IV infusionNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: INCA033989, Bioavailability enhancer | Healthy Participants | 126 | 2026-10-19 | in 61 d | 2026-07-08 |
| Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)NCT06958211Proportion of participants who achieve Hidradenitis Suppurativa (HS) Clinical Response 75 (HiSCR75) from baselineRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Ruxolitinib Cream, Vehicle Cream | Hidradenitis Suppurativa | 573 | 2026-10-09 | in 51 d | 2026-07-08 |
| Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)NCT06959225Proportion of participants who achieve Hidradenitis Suppurativa (HS) Clinical Response 75 (HiSCR75) from baselineRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Ruxolitinib Cream, Vehicle Cream | Hidradenitis Suppurativa | 580 | 2026-10-09 | in 51 d | 2026-07-28 |
| A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell CarcinomaNCT05888844Objective response rate (ORR)Randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: INCB099280 | Cutaneous Squamous Cell Carcinoma | 63 | 2026-09-28 | in 40 d | 2026-08-17 |
| A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult ParticipantsNCT07588139Pharmacokinetics Parameter (PK): Cmax of dermal interstitial fluid (dISF) ruxolitinibNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Povorcitinib, Ruxolitinib | Healthy Participants | 24 | 2026-09-03 | in 15 d | 2026-06-03 |
| Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL PatientsNCT04824092PFS-INVRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Tafasitamab, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo | Diffuse Large B-cell Lymphoma | 899 | 2026-09-01 | in 13 d | 2026-04-01 |
| A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental VitiligoNCT06548360Proportion of Participants Achieving a ≥ 75% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI75)Randomized · Triple-masked · Treatment | Phase 3 | Recruiting | Drug: Ruxolitinib Cream, Vehicle Cream | NonSegmental Vitiligo | 180 | 2026-08-10 | — | 2026-07-23 |
| A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic DermatitisNCT06832618VC Period: Binary response status of Eczema Area and Severity Index 75 (EASI75)Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Ruxolitinib, Vehicle Cream | Atopic Dermatitis | 159 | 2026-08-07actual | — | 2026-08-19 |
| A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid TumorsNCT06873789Number of participants with Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: INCB177054, Retifanlimab | Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors | 9 | 2026-07-30 | — | 2026-06-16 |
| A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor NaiveNCT05879822Objective response rate (ORR)Randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: INCB099280 | Advanced Solid Tumor | 73 | 2026-07-22 | — | 2025-12-17 |
| Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)NCT05429268Overall Response Rate (ORR)Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Tafasitamab, Lenalidomide | Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma | 82 | 2026-03-30actual | — | 2026-05-05 |
| A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)NCT06113471Proportion of Participants Achieving a ≥ 75% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI75)Randomized · Triple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Povorcitinib, Placebo | NonSegmental Vitiligo | 450 | 2026-03-17actual | — | 2026-03-31 |
| A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)NCT06113445Proportion of Participants Achieving a ≥ 75% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI75)Randomized · Triple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Povorcitinib, Placebo | NonSegmental Vitiligo | 467 | 2026-02-24actual | — | 2026-03-23 |
| INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative DisordersNCT04455841results2026-05-12Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Treatment-emergent Serious Adverse Event (SAE)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Active, not recruiting | Drug: INCB000928, ruxolitinib | Anemia, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis | 84 | 2025-04-01actual | — | 2026-05-14 |
| Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL PatientsNCT05222555results2025-07-28Number of Participants With Any Treatment-emergent Adverse Event (TEAE)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Active, not recruiting | Drug: Tafasitamab, Lenalidomide | Diffuse Large B Cell Lymphoma | 53 | 2024-07-17actual | — | 2026-01-16 |
| A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.NCT04680052results2025-04-04FL Population: Progression-free Survival (PFS) by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented Disease Progression (PD), or Death From Any Cause, Whichever Occurred FirstRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: tafasitamab, rituximab, lenalidomide, placebo | Follicular Lymphoma, Marginal Zone Lymphoma | 654 | 2024-02-23actual | — | 2025-12-22 |
| A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell LymphomaNCT04849715Progression Free SurvivalRandomized · Double-masked · Treatment | Phase 3 | Withdrawnsponsor's stated reason: business decision; no enrolled patients | Drug: parsaclisib, rituximab, bendamustine, Placebo | Mantle Cell Lymphoma | 0 | 2030-08-15 | in 1,457 d | 2022-04-29 |
| To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)NCT04796922Progression Free Survival (PFS) in R/R FL and MZL participantsRandomized · Triple-masked · Treatment | Phase 3 | Withdrawnsponsor's stated reason: This study was withdrawn due to a business decision. | Drug: parsaclisib, rituximab, obinutuzumab | Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL) | 0 | 2028-12-20 | in 854 d | 2022-07-18 |
| Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.NCT04463771Group A - Objective Response RateNon-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: retifanlimab, epacadostat, pemigatinib, INCAGN02385, INCAGN02390 | Endometrial Cancer | 206 | 2026-05-29actual | — | 2026-06-11 |
| A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Carbamazepine on INCB123667 When Administered Orally to Healthy Adult ParticipantsNCT06909162Pharmacokinetics Parameter (PK): Cmax of INCB123667Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: INCB123667, itraconazole, carbamazepine | Healthy Participants | 51 | 2026-05-17actual | — | 2026-06-15 |
| A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of ItacitinibNCT04640025Treatment Emergent Adverse Events (TEAE's)Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: The decision to close the study was made due to the expiration of remaining drug supply. | Drug: itacitinib | Myelofibrosis, Postlung Transplant (Bronchiolitis Obliterans), Chronic Graft Versus Host Disease | 18 | 2026-05-11actual | — | 2026-06-26 |
| A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic LeukemiaNCT02723994Part 1: Safety/tolerability of ruxolitinib in combination with chemotherapy as measured by adverse events (AEs), vital signs, clinical laboratory tests, and echocardiogramsOpen-label · Treatment | Phase 2 | Completed | Drug: Ruxolitinib, Asparaginase Erwinia Chrysanthemi, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Thioguanine, Vincristine Sulfate | Leukemia | 171 | 2026-03-03actual | — | 2026-03-11 |
| Study of INCB040093 in Subjects With Previously Treated B-Cell MalignanciesNCT01905813Safety and tolerability of INCB040093 as monotherapy and when given in combination with itacitinib as determined by clinical laboratory assessments, physical exams, 12-lead ECG and summary of adverse eventsNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: INCB040093, INCB040093 + itacitinib | B-cell Malignancies | 121 | 2026-02-26actual | — | 2026-05-11 |
| realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCLNCT04981795observationalTreatment Patterns - Safety | — | Completed | Drug: Tafasitamab | Diffuse Large B-cell Lymphoma | 102 | 2026-01-23actual | — | 2026-04-27 |
| An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung CancerNCT02917993Phase 1: Frequency, severity, and duration of adverse events (AEs)Open-label · Treatment | Phase 1/2 | Completed | Drug: Itacitinib, Osimertinib | Lung Cancer | 59 | 2025-12-24actual | — | 2026-02-09 |
| A Study to Evaluate Microneedle-based Collection of Dermal Interstitial Skin Fluid in Healthy Participants and Atopic Dermatitis ParticipantsNCT06934980observationalVolume of dISF collected from normal skin in healthy participants and lesional skin from AD patients | — | Completed | Device: Microneedle Device | Atopic Dermatitis, Healthy Volunteers | 20 | 2025-12-19actual | — | 2026-01-16 |
| Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB123667 in Healthy Male ParticipantsNCT07218744Total Recovery (Urine + Feces) of the Administered RadioactivityOpen-label · Treatment | Phase 1 | Completed | Drug: INCB123667 | Healthy Participants | 9 | 2025-12-10actual | — | 2026-01-07 |
| Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced MalignanciesNCT05577182Part 1: Occurrence of Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: INCA32459-101 | Advanced Malignancies | 46 | 2025-10-13actual | — | 2025-11-03 |
| Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB000631 When Administered Orally to Healthy Adult ParticipantsNCT07039929Number of participants with Treatment-emergent Adverse Events (TEAEs)Randomized · Triple-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: Strategic Business Decision | Drug: INCB000631, Placebo | Healthy Participants | 24 | 2025-10-11actual | — | 2025-10-29 |
| A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy ParticipantsNCT07018635Pharmacokinetics Parameter (PK): Cmax of INCB161734Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: INCB161734, Itraconazole, Rifampin, Esomeprazole, Famotidine | Healthy Participants | 63 | 2025-09-29actual | — | 2025-11-26 |
| A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced MalignanciesNCT03522142Part 1 (1A and 1B): Number of treatment-emergent adverse events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The study was terminated after careful review of the overall clinical activity of this compound and a lack of robust efficacy. The study closure is not based on safety concerns. | Drug: INCB081776, INCMGA00012 | Advanced Solid Tumors | 83 | 2025-09-10actual | — | 2025-10-09 |
| Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced MalignanciesNCT04370704results2026-08-17Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: INCAGN02385, INCAGN02390, INCMGA00012. | Melanoma | 61 | 2025-08-25actual | — | 2026-08-17 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adult ParticipantNCT06213818Number of participants with Treatment Emergent Adverse Events (TEAEs)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: INCB160058, Placebo, Esomeprazole, Famotidine | Healthy Participants | 137 | 2025-08-19actual | — | 2025-10-14 |
| A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib CreamNCT06213831Number of participants with Treatment-emergent Adverse Events (TEAEs)Open-label · Treatment | Phase 1 | Completed | Drug: Ruxolitinib Cream 1.5% | Prurigo Nodularis | 23 | 2025-07-17actual | — | 2025-08-13 |
| A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic CholangiocarcinomaNCT03656536results2026-08-11Randomized Treatment Period: Progression-free Survival (PFS)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: The study was terminated due to lack of enrollment resulting from a change in the standard of care for the first-line treatment of patients with cholangiocarcinoma. There were no safety concerns that contributed to this decision. | Drug: Pemigatinib, Gemcitabine, Cisplatin | Unresectable Cholangiocarcinoma, Metastatic Cholangiocarcinoma | 167 | 2025-07-07actual | — | 2026-08-11 |
| A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid TumorsNCT05949632results2026-06-04Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: This was a strategic business decision. There were no safety concerns contributing to this decision. | Drug: INCB099280, axitinib | Advanced Solid Tumors | 5 | 2025-06-06actual | — | 2026-06-04 |
| A Study to Evaluate a Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy ParticipantsNCT06713590Pharmacokinetics Parameter: Cmax of axatilimabRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Axatilimab | Healthy Participants | 72 | 2025-06-06actual | — | 2025-06-25 |
| A Study to Evaluate the Relative Bioavailability of New Formulations of INCB057643 Tablets Administered Orally in Healthy ParticipantsNCT06941077Pharmacokinetics Parameter (PK): Cmax of INCB057643Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: INCB057643 | Healthy Volunteers | 48 | 2025-06-03actual | — | 2025-06-11 |
| Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, & Food Effect of Oral INCB000631 to Healthy Adult ParticipantsNCT06775327Number of participants with Treatment-emergent Adverse Events (TEAEs)Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: INCB000631, Placebo | Healthy Participants | 71 | 2025-05-28actual | — | 2025-06-11 |
| A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic DermatitisNCT06238817results2026-05-22Percentage of Participants Achieving a ≥75% Improvement in the Eczema Area and Severity Index Score (EASI75) at Week 8Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Ruxolitinib Cream, Vehicle Cream | Atopic Dermatitis | 241 | 2025-05-21actual | — | 2026-05-22 |
| A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C MutationNCT06039384Part 1: Number of participants with Dose Limiting Toxicities (DLTs)Randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: This was a strategic business decision. There were no safety concerns contributing to this decision. | Drug: INCB099280, adagrasib | Advanced Solid Tumors | 6 | 2025-04-11actual | — | 2025-08-03 |
| A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital VitiligoNCT05750823results2026-03-20Percentage of Participants Achieving a Genital Vitiligo Noticeability Scale (VNS) of "4 - A Lot Less Noticeable" or "5 - No Longer Noticeable" at Week 48Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Ruxolitinib Cream | Nonsegmental Vitiligo With Genital Involvement | 49 | 2025-03-06actual | — | 2026-03-20 |
| Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous UrticariaNCT05936567results2026-03-12Change From Baseline in the Urticaria Activity Score Over 7 Days (UAS7) at Week 12Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Povorcitinib, Placebo | Urticaria, Chronic Spontaneous Urticaria, Chronic Idiopathic Urticaria, Hives, Angioedema, Pruritis | 136 | 2025-02-28actual | — | 2026-03-12 |
| A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis SuppurativaNCT05620823Proportion of participants who achieve Hidradenitis Suppurativa Clinical Response (HiSCR)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Povorcitinib, Placebo | Hidradenitis Suppurativa (HS) | 608 | 2025-02-03actual | — | 2026-02-10 |
| The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.NCT05696392results2025-12-19Change From Baseline in Total Sleep Time (TST) as Measured by Ōura Ring Wearable Device at Week 8Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Terminatedsponsor's stated reason: The study was terminated due to lack of enrollment. | Drug: ruxolitinib cream | Atopic Dermatitis | 47 | 2025-01-22actual | — | 2025-12-19 |
| A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult ParticipantsNCT06416800Pharmacokinetic (PK) in plasma digoxinRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Digoxin, Rosuvastatin, Metformin, Povorcitinib, Probenecid | Healthy Participants | 71 | 2025-01-15actual | — | 2025-02-06 |
| A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)NCT05620836Proportion of participants who achieve Hidradenitis Suppurativa Clinical Response (HiSCR)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Povorcitinib, Placebo | Hidradenitis Suppurativa (HS) | 619 | 2025-01-07actual | — | 2026-01-09 |
| A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)NCT05764161results2025-11-24WI-NRS4 Response at Week 12Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Ruxolitinib Cream, Vehicle Cream | Prurigo Nodularis | 190 | 2024-12-30actual | — | 2025-12-18 |
| Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 AlterationsNCT05267106results2025-12-30Objective Response Rate (ORR) in Participants With Recurrent Glioblastoma Based on Independent Central ReviewNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Recruitment ceased after a pre-planned futility interim analysis indicated a low probability to confer a clinically meaningful improvement in objective response when compared to currently available therapies. There were no safety related concerns. | Drug: Pemigatinib | Glioblastoma, Adult-type Diffuse Gliomas | 83 | 2024-12-17actual | — | 2025-12-30 |
| A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)NCT03011372results2025-11-18Percentage of Participants Who Achieved Complete Response (CR) as Determined by Investigator Assessment According to the Response Criteria for Myeloid/Lymphoid Neoplasms With FGFR1 RearrangementOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Pemigatinib | MPN (Myeloproliferative Neoplasms) | 47 | 2024-10-30actual | — | 2025-11-18 |
| A Study to Evaluate the Bioequivalence of Ruxolitinib Extended Release (XR) Tablets With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy ParticipantsNCT06555081INCB018424 pharmacokinetic (PK) in PlasmaRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Ruxolitinib IR, Ruxolitinib XR | Healthy Participants | 168 | 2024-10-25actual | — | 2025-02-13 |
| A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)NCT04809467results2026-01-29Number of Participants With Any Treatment-emergent Adverse Event (TEAE )Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision. | Drug: tafasitamab, parsaclisib | Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma | 54 | 2024-10-22actual | — | 2026-02-04 |
| A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)NCT05755438results2025-11-14WI-NRS4 Response at Week 12Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Ruxolitinib Cream, Vehicle Cream | Prurigo | 204 | 2024-10-07actual | — | 2026-08-12 |
| Study of INCA 0186 in Subjects With Advanced Solid TumorsNCT04989387Evaluation of the safety and tolerability of INCA00186 as monotherapy and in combination with retifanlimab and/or INCB106385 as measured by the number of participants with adverse eventsductions and withdrawal of treatment due to AEsNon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: This was a strategic business decision. There were no safety concerns contributing to this decision. | Drug: INCA00186, Retifanlimab, INCB106385 | Advanced Solid Tumors, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Gastrointestinal (GI) Malignancies | 57 | 2024-09-19actual | — | 2025-09-02 |
| Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid TumorsNCT05909995Occurence of DLTsNon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: This was a strategic business decision. There were no safety concerns contributing to this decision. | Drug: INCB 99280 with Ipilimumab | Melanoma, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC), Microsatellite Instability - High (MSI-H), Mismatch Repair Deficient (dMMR), Colorectal Carcinoma (CRC) | 8 | 2024-09-19actual | — | 2025-02-18 |
| A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy ParticipantsNCT06505265Pharmacokinetic (PK) in dermal povorcitinibOpen-label · Treatment | Phase 1 | Completed | Drug: Povorcitinib | Healthy Participants | 18 | 2024-09-18actual | — | 2024-09-26 |
| A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy ParticipantsNCT06441318Change from Baseline in QT interval corrected using Fridericia's formula (QTcF)Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: Povorcitinib, Placebo, Moxifloxacin | Healthy Participants | 128 | 2024-09-10actual | — | 2024-09-25 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid TumorsNCT04242199Number of treatment-emergent adverse eventsNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: INCB099280 | Advanced Solid Tumor, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer, HepatoCellular Carcinoma, Esophageal Squamous Cell Carcinoma, Merkel Cell Carcinoma, Small-cell Lung Cancer, Mesothelioma, PD-L1 Amplified Tumor (9p24.1), Nasopharyngeal Carcinoma | 182 | 2024-08-29actual | — | 2025-07-14 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid TumorsNCT04272034Number of treatment-emergent adverse eventsNon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision. | Drug: INCB099318 | Advanced Solid Tumors, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, HCC, Cervical Cancer, Esophageal Squamous Cell Carcinoma, Merkel Cell Carcinoma, Small-cell Lung Cancer, Mesothelioma, PD-L1 Amplified Tumor (9p24.1), Nasopharyngeal Carcinoma, Cyclin-dependent Kinase 12 Mutated Tumors, Basal Cell Carcinoma (Unresectable or Metastatic), Sarcomatoid Renal Cell Carcinoma, Clear Cell Ovarian or Endometrial Carcinoma, Anal Carcinoma, Squamous Cell Penile Carcinoma, DNA Polymerase Epsilon Mutated Tumors (P286R and V411L) | 105 | 2024-08-16actual | — | 2025-10-16 |
| To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple MyelomaNCT04582539results2025-10-22Number of Participants With Any Treatment-emergent Adverse Event (TEAE)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Strategic Business Decision | Drug: INCB000928 | Myelodysplastic Syndromes, Multiple Myeloma, Anemia | 22 | 2024-08-15actual | — | 2025-10-22 |
| Topical Ruxolitinib Evaluation in Chronic Hand EczemaNCT05906628results2025-07-31Percentage of Participants With Investigator's Global Assessment-Chronic Hand Eczema Treatment Success (IGA-CHE-TS) at Week 16Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Ruxolitinib cream, Vehicle | Hand Eczema | 186 | 2024-07-15actual | — | 2025-07-31 |
| A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)NCT02763319results2025-07-17Kaplan-Meier Estimate of Progression-Free Survival by Independent Radiology/Clinical Review Committee Assessment in the Overall PopulationRandomized · Single-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Completed | Drug: Rituximab (RTX), Tafasitamab, Bendamustine (BEN) | Diffuse Large B-cell Lymphoma | 453 | 2024-06-21actual | — | 2025-07-17 |
| A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult FemalesNCT06380205Levonorgestrel (LNG) concentration in plasmaOpen-label · Treatment | Phase 1 | Completed | Drug: Povorcitinib, Levonorgestrel/Ethinyl estradiol | Healthy Participants | 24 | 2024-06-07actual | — | 2024-07-03 |
| A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]INCB099280 in Healthy Male ParticipantsNCT06309394results2025-09-11Total Recovery (Urine + Feces) of the Administered RadioactivityOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: INCB099280 | Healthy Participants | 5 | 2024-06-04actual | — | 2025-09-11 |
| A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid TumorsNCT03059823Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.03Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: retifanlimab | Locally Advanced Solid Tumors, Metastatic Solid Tumors | 325 | 2024-05-22actual | — | 2025-08-03 |
| Study of Ruxolitinib Cream in Adolescents With Atopic DermatitisNCT05456529results2025-06-25Number of Participants With Treatment-emergent Adverse Events (TEAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Ruxolitinib Cream | Atopic Dermatitis (AD) | 103 | 2024-05-17actual | — | 2025-06-25 |
| A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) InhibitorNCT03235544results2022-02-10Objective Response Rate (ORR)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Parsaclisib | Lymphoma | 162 | 2024-04-30actual | — | 2025-03-18 |
| Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1NCT05219864Proportion of participants achieving Investigator's Global Assessment-Chronic Hand Eczema Treatment Success (IGA-CHE-TS)Randomized · Triple-masked · Treatment | Phase 3 | Withdrawnsponsor's stated reason: Business decision; no safety concerns. | Drug: Ruxolitinib cream, Vehicle | Hand Eczema | 0 | 2024-04-25 | — | 2022-11-17 |
| Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2NCT05233410Percentage of Participants achieving Investigator's Global Assessment-Chronic Hand Eczema Treatment Success (IGA-CHE-TS)Randomized · Triple-masked · Treatment | Phase 3 | Withdrawnsponsor's stated reason: Business decision; no safety concerns | Drug: Ruxolitinib cream, Vehicle | Chronic Hand Eczema (CHE) | 0 | 2024-04-25 | — | 2022-11-10 |
| A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.NCT06310304INCB018424 pharmacokinetic (PK) in PlasmaRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Ruxolitinib IR, Ruxolitinib XR | Healthy Participants | 24 | 2024-04-16actual | — | 2024-06-05 |
| Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).NCT04472429results2025-05-23Progression-free Survival (PFS)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: carboplatin, paclitaxel, retifanlimab | Squamous Cell Carcinoma of the Anal Canal | 308 | 2024-04-15actual | — | 2025-11-03 |
| The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.NCT04949191results2024-09-19Number of Participants With Any Treatment-emergent Adverse Event (TEAE)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: A business decision due to availability of commercial drug and other options for accessing study drug treatment. | Drug: Pemigatinib, Retifanlimab, Pembrolizumab | Advanced Malignancies | 10 | 2024-04-11actual | — | 2024-09-19 |
| Study of INCB086550 in Select Solid TumorsNCT04629339results2025-03-13Objective Response Rate (ORR)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Strategic business decision to terminate the study effective immediately. This is due to a company decision to prioritize another oral PD-L1 inhibitor with a more favorable profile. | Drug: INCB086550 | Non Small Cell Lung Cancer, Urothelial Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma, Melanoma | 16 | 2024-03-26actual | — | 2025-03-13 |
| Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on HemodialysisNCT05624723Pharmacokinetics Parameter: Cmax of INCB054707Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: INCB054707 | Renal Insufficiency, Kidney Diseases | 43 | 2024-02-07actual | — | 2024-02-13 |
| An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial CarcinomaNCT04586244results2025-03-10Change From Baseline in CD8+ Lymphocytes Within the Resected TumorRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Business Decision. No safety concerns contributed to this decision. | Drug: retifanlimab, epacadostat, INCAGN02385, INCAGN02390 | Urothelial Carcinoma | 30 | 2024-01-29actual | — | 2025-10-30 |
| INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid TumorsNCT04580485Number of treatment-emergent adverse events (TEAE)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: INCB106385, INCMGA00012 | Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Castration Resistant Prostate Cancer, Colorectal Cancer, Gastric/ Gastroesophageal Junction, Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Squamous Carcinoma of the Anal Canal | 54 | 2024-01-22actual | — | 2025-07-11 |
| A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With VitiligoNCT05247489results2025-02-20Change From Baseline in Total Body Vitiligo Area Scoring Index (T-VASI) at Week 48Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Ruxolitinib 1.5% cream · Device: NB-UVB phototherapy | Vitiligo | 55 | 2023-12-19actual | — | 2025-02-20 |
| Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung CancerNCT04205812results2025-02-06Overall SurvivalRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Retifanlimab, Placebo, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, nab-Paclitaxel | Metastatic Squamous Non-Small Cell Lung Cancer, Metastatic Nonsquamous Non-Small Cell Lung Cancer | 583 | 2023-12-15actual | — | 2026-07-06 |
| INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)NCT04203511Progression-free survival (PFS)Randomized · Double-masked · Treatment | Phase 3 | Withdrawnsponsor's stated reason: Sponsor Strategic/Business Decision | Drug: Retifanlimab, Placebo, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, Etoposide · Radiation: Radiotherapy | Non-small Cell Lung Cancer | 0 | 2023-11-30 | — | 2020-06-09 |
| A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid TumorsNCT03762447Number of treatment-emergent adverse eventsOpen-label · Treatment | Phase 1 | Completed | Drug: INCB086550 | Solid Tumors | 138 | 2023-11-17actual | — | 2025-08-11 |
| GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host DiseaseNCT03584516results2025-01-27Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Terminatedsponsor's stated reason: The study was terminated due to insufficient efficacy to support moving into Part 2 of the study; there were no safety concerns that contributed to this decision. | Drug: Itacitinib, Placebo, Methylprednisolone, Prednisone | Chronic Graft-versus-host Disease | 155 | 2023-11-03actual | — | 2025-10-20 |
| Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis SuppurativaNCT05635838results2024-11-01Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 16Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Ruxolitinib cream, Vehicle cream | Hidradenitis Suppurativa | 69 | 2023-10-19actual | — | 2024-11-01 |
| Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic AnemiaNCT05073458results2025-01-15Percentage of Participants Attaining a Durable Hemoglobin ResponseRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision. | Drug: parsaclisinib, placebo | Warm Autoimmune Hemolytic Anemia (wAIHA) | 13 | 2023-10-17actual | — | 2025-11-03 |
| Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung TransplantationNCT03978637results2025-01-29Number of Participants With Any Treatment-emergent Adverse Event (TEAE)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Business Decision | Drug: Itacitinib | Bronchiolitis Obliterans Syndrome | 23 | 2023-10-13actual | — | 2025-10-20 |
| A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen PlanusNCT05593432results2024-10-24Percentage of Participants Achieving Investigator's Global Assessment-Treatment Success (IGA-TS) at Week 16Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Ruxolitinib cream, Vehicle cream | Cutaneous Lichen Planus | 64 | 2023-10-02actual | — | 2024-10-24 |
| A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen SclerosusNCT05593445results2024-09-24Percentage of Participants With ITCH4 at Week 12Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Ruxolitinib cream, Vehicle cream | Lichen Sclerosus | 61 | 2023-09-01actual | — | 2024-09-24 |
| To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)NCT04629508results2024-09-19Part 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)Non-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: itacitinib | Myelofibrosis, Polycythemia Vera, Thrombocythemia | 4 | 2023-08-24actual | — | 2025-09-02 |
| To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)NCT04551053results2024-08-23Percentage of Participants Achieving ≥25% Reduction in Spleen Volume From Baseline to Week 24 as Measured by Magnetic Resonance Imaging (MRI) (or Computed Tomography [CT] Scan in Applicable Participants)Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: The study was terminated due to futility. | Drug: parsaclisib, ruxolitinib, placebo | Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis | 177 | 2023-08-16actual | — | 2025-10-02 |
| Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR AlterationNCT05253807results2024-08-06Objective Response Rate (ORR) in Cohort ANon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Pemigatinib | Non-Small Cell Lung Cancer (NSCLC) | 8 | 2023-08-16actual | — | 2025-08-05 |
| A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo NodularisNCT05061693results2024-08-27Percentage of Participants Achieving ≥4-point Improvement in Itch Numerical Rating Scale (NRS) Score at Week 16Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: INCB054707, Placebo | Prurigo Nodularis | 146 | 2023-08-11actual | — | 2025-07-11 |
| Study of Ruxolitinib Cream in Children With Atopic DermatitisNCT05034822Number of treatment-emergent adverse eventsOpen-label · Treatment | Phase 1 | Completed | Drug: Ruxolitinib cream | Atopic Dermatitis | 29 | 2023-08-07actual | — | 2023-09-15 |
| To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)NCT04551066results2024-10-04Percentage of Participants Achieving ≥35% Reduction in Spleen Volume From Baseline to Week 24 as Measured by Magnetic Resonance Imaging [MRI] (or Computed Tomography [CT] Scan in Applicable Participants)Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: The study was terminated due to futility. | Drug: parsaclisib, ruxolitinib, placebo | Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis | 252 | 2023-08-03actual | — | 2025-10-21 |
| Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis InvolvementNCT05127421results2024-08-15Percentage of Participants Who Achieve a ≥75% Improvement in the Eczema Area and Severity Index Score (EASI75) of the Head and Neck Region at Week 4Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Ruxolitinib cream, Vehicle | Atopic Dermatitis | 77 | 2023-08-03actual | — | 2024-08-15 |
| A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic ImpairmentNCT05624710Pharmacokinetics Parameter: Cmax of INCBC054707Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: INCB054707 | Renal Insufficiency, Kidney Diseases | 25 | 2023-06-30actual | — | 2025-08-03 |
| A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)NCT04921969results2024-06-10VC Period: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Ruxolitinib, Vehicle Cream | Atopic Dermatitis | 330 | 2023-05-10actual | — | 2025-03-28 |
| A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell TherapyNCT04071366results2024-03-26Percentage of Participants Who Developed ≥Grade 2 Cytokine Release Syndrome (CRS) by Day 14 After Immune Effector Cell (IEC) Therapy, Assessed by Using American Society for Blood and Marrow Transplantation (ASBMT) CRS Consensus GradingRandomized · Triple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Itacitinib, Immune effector cell therapy, Placebo · Biological: Yescarta | Cytokine Release Syndrome | 112 | 2023-02-23actual | — | 2024-03-26 |
| Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and HemodialysisNCT05099445PK for plasma of INCB000928: CmaxNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: INCB000928 | Renal Impairment, Hemodialysis | 48 | 2023-02-19actual | — | 2023-05-15 |
| A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid TumorsNCT03314935results2023-12-07Phases 1 and 2: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: INCB001158, Oxaliplatin, Leucovorin, 5-Fluorouracil, Gemcitabine, Cisplatin, Paclitaxel | Biliary Tract Cancer (BTC), Colorectal Cancer (CRC), Endometrial Cancer, Gastroesophageal Cancer (GC), Ovarian Cancer, Solid Tumors | 149 | 2022-11-28actual | — | 2025-08-12 |
| INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid TumorsNCT03589651Number of treatment-emergent adverse eventsNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Retifanlimab, Epacadostat, INCB050465 | Unresectable or Metastatic Solid Tumors | 83 | 2022-11-21actual | — | 2023-02-21 |
| The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic DermatitisNCT04839380results2023-10-31Change From Baseline in the Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Day 2 (24-hour Recall Period After First Application)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: ruxolitinib cream | Atopic Dermatitis | 49 | 2022-11-18actual | — | 2023-10-31 |
| A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)NCT04896385results2023-12-07Percentage Change From Baseline in Chemokine (C-X-C Motif) Ligand 10 (CXCL10), an Immune Biomarker, at Week 4, Week 12, and Week 24Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Ruxolitinib cream, Vehicle Cream | Vitiligo | 60 | 2022-11-17actual | — | 2025-08-05 |
| Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With VitiligoNCT04530344results2023-07-19Time to Relapse (Defined as <F-VASI75)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: ruxolitinib, Vehicle | Vitiligo | 458 | 2022-11-14actual | — | 2025-08-14 |
| To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.NCT04831996Pharmacokinetics Parameter Groups1-4 : Cmax of parsaclisibNon-randomized · Open-label · Other | Phase 1 | Completed | Drug: parsaclisib | Advanced Malignancies | 48 | 2022-07-08actual | — | 2022-08-17 |
| INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)NCT03424122Number of treatment-emergent adverse events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Parsaclisib, Rituximab, Bendamustine, Ibrutinib | B-cell Lymphoma | 50 | 2022-06-27actual | — | 2025-08-21 |
| A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell LymphomaNCT02760485results2023-06-15Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: itacitinib, ibrutinib | Lymphoma | 33 | 2022-06-06actual | — | 2023-06-15 |
| A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With VitiligoNCT04818346results2023-07-05Percent Change From Baseline in Total Vitiligo Area Scoring Index (T-VASI) at Week 24Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: INCB054707, Placebo | NonSegmental Vitiligo | 171 | 2022-05-24actual | — | 2024-04-11 |
| An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced MalignanciesNCT02712905results2023-06-12Number of Participants Receiving INCB059872 Monotherapy With Any Treatment-emergent Adverse Event (TEAE)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Strategic Business Decision | Drug: INCB059872, all-trans retinoic acid (ATRA), azacitidine, nivolumab | Solid Tumors and Hematologic Malignancy | 116 | 2022-04-14actual | — | 2025-11-04 |
| INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple MyelomaNCT03837509results2023-03-20Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: This decision follows recruitment difficulties. No safety-related concerns impacted this decision. | Drug: INCB001158 · Biological: Daratumumab SC | Relapsed or Refractory Multiple Myeloma | 15 | 2022-04-05actual | — | 2025-11-04 |
| Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)NCT02953704observationalDescription of the clinical characteristics and evolution of disease burden in essential thrombocythemia (ET) and myelofibrosis (MF) patients | — | Completed | — | MPN (Myeloproliferative Neoplasms) | 1,469 | 2022-03-29actual | — | 2022-05-13 |
| Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)NCT03822117results2023-03-15Objective Response Rate (ORR), Defined as the Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) Based on RECIST v1.1 or RANO, in Participants With FGFR1-3 In-frame Fusions or FGFR2 ArrangementsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: A business decision was made to to discontinue further enrollment. There were no safety concerns that contributed to this decision. | Drug: Pemigatinib | Solid Tumor Malignancy | 111 | 2022-03-29actual | — | 2025-11-04 |
| A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB086550NCT05101369Total recovery of radioactivity from urine and feces.Open-label · Treatment | Phase 1 | Completed | Drug: INCB086550 | Healthy Volunteers | 7 | 2022-03-25actual | — | 2025-08-21 |
| To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.NCT04831944Pharmacokinetics Parameter : Cmax of parsaclisibNon-randomized · Open-label · Other | Phase 1 | Completed | Drug: parsaclisib | Advanced Malignancies | 21 | 2022-03-10actual | — | 2022-08-26 |
| A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)NCT02872714results2023-03-24Objective Response Rate (ORR) in Participants With FGFR3 Mutations or Fusions on a CD RegimenRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: pemigatinib, pemigatinib | UC (Urothelial Cancer) | 263 | 2022-02-01actual | — | 2025-08-14 |
| Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)NCT02924376results2023-02-23Objective Response Rate (ORR) in Participants With FGFR2 Rearrangements or FusionsNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Pemigatinib | Cholangiocarcinoma | 147 | 2022-02-01actual | — | 2025-08-14 |
| A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)NCT03599713results2023-05-03Objective Response Rate (ORR)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Retifanlimab | Metastatic Merkel Cell Carcinoma | 107 | 2022-01-21actual | — | 2025-08-05 |
| Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)NCT02393248results2023-01-06Parts 1 and 2 Combined: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminated | Drug: Pemigatinib, Gemcitabine, Pembrolizumab, Docetaxel, Trastuzumab, Retifanlimab, Cisplatin | Lung Cancer, Solid Tumor, Gastric Cancer, Urothelial Cancer, Endometrial Cancer, Multiple Myeloma, Myeloproliferative Neoplasms, Breast Cancer, Cholangiocarcinoma, UC, MPN | 201 | 2021-12-17actual | — | 2023-01-06 |
| To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis SuppurativaNCT04476043results2023-01-26Mean Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 16Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: INCB054707, Placebo | Hidradenitis Suppurativa, Acne Inversa | 209 | 2021-12-15actual | — | 2025-08-12 |
| A Safety and Tolerability Study of INCAGN02390 in Select Advanced MalignanciesNCT03652077Number of treatment-emergent adverse eventsOpen-label · Treatment | Phase 1 | Completed | Drug: INCAGN02390 | Cervical Cancer, Gastric Cancer, Stomach Cancer, Gastroesophageal Junction Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Melanoma, Uveal Melanoma, Merkel Cell Carcinoma, Mesothelioma, MSI, Non-small Cell Lung Cancer, NSCLC, Ovarian Cancer, Squamous Cell Carcinoma of the Head and Neck, Small Cell Lung Cancer, Renal Cell Carcinoma, RCC, Triple-negative Breast Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency | 40 | 2021-08-18actual | — | 2021-11-15 |
| A Study of INCB050465 in Participants With Autoimmune Hemolytic AnemiaNCT03538041results2022-09-22Percentage of Participants Attaining a Complete Response at Any Visit From Week 6 to Week 12Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Parsaclisib | Autoimmune Hemolytic Anemia | 25 | 2021-08-05actual | — | 2025-07-11 |
| Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)NCT04003610results2022-05-25Progression-free Survival (PFS)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: The reason this study was terminated was due to a business decision. There were no safety concerns that contributed to this decision. | Drug: Pemigatinib, Pembrolizumab, Gemcitabine, Carboplatin | Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma | 7 | 2021-04-18actual | — | 2025-11-04 |
| A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)NCT03679767results2022-05-10Overall Response Rate (ORR)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Retifanlimab | Metastatic Non-small Cell Lung Cancer, Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer, Unresectable Melanoma, Metastatic Melanoma, Locally Advanced Renal Cell Carcinoma, Metastatic Clear-Cell Renal Cell Carcinoma | 121 | 2021-04-15actual | — | 2023-07-21 |
| A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)NCT02018861results2022-06-28Number of Participants With Treatment-emergent Adverse Events (TEAEs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: Parsaclisib, Itacitinib, Rituximab, Ifosfamide, Carboplatin, Etoposide | B-Cell Malignancies | 88 | 2021-04-12actual | — | 2023-09-28 |
| Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)NCT03039114Safety and tolerability of parsaclisib in combination with bendamustine and obinutuzumab in relapsed or refractory FL, assessed by number of subjects with adverse events (AEs)Open-label · Treatment | Phase 1 | Completed | Drug: Parsaclisib, Hexal, Gazyvaro | Lymphoma | 26 | 2021-03-30actual | — | 2025-08-21 |
| Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)NCT04052425results2022-09-21Percentage of Participants Achieving a ≥ 75% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI75) Score at Week 24Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Ruxolitinib cream, Vehicle | Non-segmental Vitiligo | 330 | 2021-03-18actual | — | 2025-08-22 |
| Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)NCT04057573results2022-09-21Percentage of Participants Achieving a ≥ 75% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI75) Score at Week 24Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Ruxolitinib cream, Vehicle | Non-segmental Vitiligo | 344 | 2021-03-15actual | — | 2025-08-22 |
| A Study of INCB050465 in Relapsed or Refractory Follicular LymphomaNCT03126019results2022-02-10Objective Response Rate With Parsaclisib Based on Lugano Classification Response CriteriaNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Parsaclisib | Lymphoma | 126 | 2021-02-26actual | — | 2025-03-14 |
| Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)NCT04377620results2022-01-19Percentage of Participants Who Have Died Due to Any CauseRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Study terminated by sponsor | Drug: Placebo, Ruxolitinib | COVID-19 | 211 | 2021-02-26actual | — | 2022-01-19 |
| GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host DiseaseNCT03320642Proportion of participants with hematologic recovery when itacitinib is added to GVHD prophylaxis treatmentOpen-label · Prevention | Phase 1 | Terminatedsponsor's stated reason: Study terminated by sponsor | Drug: Itacitinib, Calcineurin inhibitor | Hematologic Malignancies | 84 | 2021-02-25actual | — | 2025-10-21 |
| A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)NCT03347123results2022-02-28Phase 1: Percentage of Participants With At Least One Treatment Emergent Adverse Events (TEAEs)Non-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: A business decision made by Incyte after analysis of data from a sister study. | Drug: Epacadostat, Nivolumab, Ipilimumab, Lirilumab | Solid Tumors | 11 | 2021-01-29actual | — | 2022-02-28 |
| A Study of INCB050465 in Combination With Ruxolitinib in Subjects With MyelofibrosisNCT02718300results2024-05-01Number of Participants With Dose-limiting Toxicities (DLTs)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision. | Drug: Parsaclisib, Parsaclisib, Ruxolitinib, Parsaclisib, Parsaclisib | MPN (Myeloproliferative Neoplasms) | 74 | 2021-01-28actual | — | 2024-05-01 |
| A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)NCT03144674results2022-02-10Objective Response Rate (ORR) Based on Lugano Classification CriteriaNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Parsaclisib | Lymphoma | 110 | 2021-01-15actual | — | 2025-07-11 |
| A Study of the Safety and Tolerability of INCB050465 in Pemphigus VulgarisNCT03780166Number of treatment-emergent adverse eventsOpen-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: The study was withdrawn due to insufficient interest in study participation due to recent approval in this rare condition. | Drug: Parsaclisib | Pemphigus Vulgaris | 0 | Nov 2020 | — | 2019-09-13 |
| A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic DermatitisNCT03257644Participants with treatment-emergent adverse events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Ruxolitinib phosphate cream | Atopic Dermatitis | 70 | 2020-10-07actual | — | 2020-11-10 |
| A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell LymphomaNCT03688152Number of treatment-emergent adverse events (TEAEs)Open-label · Treatment | Phase 1 | Completed | Drug: INCB053914, INCB050465 | Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 9 | 2020-09-01actual | — | 2020-11-10 |
| Study of INCB053914 in Subjects With Advanced MalignanciesNCT02587598results2021-12-08Determination of the Safety and Tolerability of INCB053914 as Measured by the Number of Participants With Adverse EventsNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminated | Drug: INCB053914, I-DAC (Intermediate dose cytarabine), Azacitidine, Ruxolitinib | Solid Tumors | 97 | 2020-08-11actual | — | 2021-12-08 |
| Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)NCT03123588results2021-11-19Proportion of Subjects Who Achieve Platelet and White Blood Cell (WBC) ControlRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Enrollment issues | Drug: Ruxolitinib, Anagrelide, Placebo, Placebo | MPN (Myeloproliferative Neoplasms) | 12 | 2020-08-03actual | — | 2021-11-19 |
| A Study of INCB059872 in Relapsed or Refractory Ewing SarcomaNCT03514407Number of adverse eventsOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Strategic Business Decision | Drug: INCB059872 | Relapsed Ewing Sarcoma | 25 | 2020-06-25actual | — | 2025-10-21 |
| A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)NCT02327078results2023-04-26Phase 1, Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: Nivolumab, Epacadostat, Chemotherapy | B-cell Malignancies, Colorectal Cancer (CRC), Head and Neck Cancer, Lung Cancer, Lymphoma, Melanoma, Ovarian Cancer, Glioblastoma | 307 | 2020-06-16actual | — | 2025-08-14 |
| Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)NCT04003623results2022-04-21Objective Response Rate (ORR)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: The study was closed due to lack of enrollment. | Drug: Pemigatinib | Advanced or Metastatic Solid Tumors, FGFR Mutations, FGFR Translocations | 1 | 2020-06-12actual | — | 2022-05-10 |
| An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other MalignanciesNCT03144661Safety and tolerability of INCB062079 as measured by assessment of adverse events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Strategic Business Decision | Drug: INCB062079 | Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Esophageal Cancer, Nasopharyngeal Cancer, Ovarian Cancer, Solid Tumors | 25 | 2020-06-10actual | — | 2025-10-21 |
| A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)NCT03597295results2021-08-23Objective Response Rate (ORR)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Retifanlimab | Squamous Cell Carcinoma of Anal Canal | 94 | 2020-06-08actual | — | 2025-08-21 |
| A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)NCT03112603results2022-04-15Efficacy of Ruxolitinib Versus Investigator's Choice Best Available Therapy (BAT) in Participants With Moderate or Severe Steroid Refractory Chronic Graft Versus Host Disease (SR-cGvHD) Assessed by Overall Response Rate (ORR) at the Cycle 7 Day 1 VisitRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib | Graft-versus-host Disease (GVHD) | 330 | 2020-05-08actual | — | 2025-08-12 |
| A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)NCT03314922Number of participants with treatment-emergent adverse events (TEAEs)Open-label · Treatment | Phase 1 | Completed | Drug: Parsaclisib | Lymphoma | 17 | 2020-05-05actual | — | 2023-08-14 |
| Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid TumorsNCT02903914results2021-09-30Number of Participants With Any Treatment-emergent Adverse Event (TEAE)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: INCB001158, Pembrolizumab | Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer, Head and Neck Cancer, Lung Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, UC (Urothelial Cancer), Mesothelioma | 260 | 2020-04-30actual | — | 2025-08-05 |
| Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia.NCT01641107Proportion of patients who are in Complete Hematological Response (CHR).Open-label · Treatment | Phase 2 | Completed | Drug: Ponatinib | Philadelphia Positive, BCR-ABL Positive, Acute Lymphoblastic Leukemia | 44 | 2020-04-24actual | — | 2021-11-30 |
| A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With MyelofibrosisNCT03144687results2021-07-02Change in Spleen Volume at Week 24 Compared to BaselineNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Itacitinib, Ruxolitinib | MPN (Myeloproliferative Neoplasms) | 23 | 2020-03-14actual | — | 2022-06-16 |
| A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)NCT03235570Safety and tolerability assessed by monitoring frequency, duration, and severity of adverse events (AEs)Open-label · Treatment | Phase 1 | Completed | Drug: Pemigatinib | Solid Tumors | 44 | 2020-03-04actual | — | 2020-05-29 |
| Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric SubjectsNCT03721965results2023-02-21Phase 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: The study was terminated due to insufficient efficacy in a separate phase III study | Drug: Itacitinib, Corticosteroids | Acute Graft-versus-host Disease | 2 | 2020-02-17actual | — | 2025-11-04 |
| Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)NCT01317875results2022-03-09Number of Participants With Dose Limiting ToxicitiesRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Ruxolitinib | Myelofibrosis | 69 | 2019-12-31actual | — | 2025-08-22 |
| A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic DermatitisNCT03920852Number of treatment-emergent adverse eventsOpen-label · Treatment | Phase 1 | Completed | Drug: Ruxolitinib cream | Atopic Dermatitis | 41 | 2019-12-26actual | — | 2020-02-17 |
| Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic DermatitisNCT03745638results2021-12-17Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Ruxolitinib Cream, Vehicle Cream | Atopic Dermatitis | 631 | 2019-12-23actual | — | 2023-09-28 |
| A Study of INCB050465 in Primary Sjögren's SyndromeNCT03627065results2021-03-24Proportion of Participants With a 1 Point or Greater Change on the Salivary Gland Ultrasound (SGUS) Score for Parotid and Submandibular GlandsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Parsaclisib | Primary Sjögren's Syndrome | 10 | 2019-12-07actual | — | 2021-08-13 |
| Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese SubjectsNCT03497273Number of treatment-emergent adverse eventsOpen-label · Treatment | Phase 1 | Completed | Drug: Itacitinib, Corticosteroid | Acute Graft-versus-host Disease | 14 | 2019-11-30actual | — | 2020-03-03 |
| TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic DermatitisNCT03745651results2021-12-17VC Period: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Ruxolitinib cream, Vehicle cream | Atopic Dermatitis | 618 | 2019-11-18actual | — | 2023-09-28 |
| A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative ColitisNCT03627052Proportion of participants with a Clinical ResponseRandomized · Double-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Study withdrawn due to lack of recruitment. No patients enrolled. No safety concerns. | Drug: Itacitinib, Placebo | Moderate to Severe Ulcerative Colitis | 0 | 2019-11-13actual | — | 2019-12-06 |
| Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid TumorsNCT02646748Part 1: Evaluation of safety and tolerability as measured by the frequency, duration, and severity of adverse eventsNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Pembrolizumab, itacitinib, INCB050465 | Colorectal Cancer (CRC), Endometrial Cancer, Melanoma, Head and Neck Cancer, Lung Cancer, MMR-deficient Tumors, Breast Cancer, Pancreatic Cancer, Renal Cell Carcinoma (RCC), Solid Tumors, UC (Urothelial Cancer) | 159 | 2019-11-07actual | — | 2022-03-31 |
| INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)NCT03920839Number of treatment-emergent adverse events with INCMGA00012 in combination with chemotherapyNon-randomized · Open-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: As of November 4, 2019 the study was halted prematurely and will not resume. | Drug: Retifanlimab, Gemcitabine, Cisplatin, Pemetrexed, Carboplatin, Paclitaxel | Advanced and/or Metastatic Solid Tumors, Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer, Advanced/Metastatic Unresectable Malignant Pleural Mesothelioma | 0 | 2019-11-04actual | — | 2020-04-24 |
| A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)NCT02318277results2020-12-29Phase 1 : Number of Treatment-Emergent Adverse Events (TEAE)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: MEDI4736, INCB024360 | Solid Tumors, Head and Neck Cancer, Lung Cancer, UC (Urothelial Cancer) | 176 | 2019-08-28actual | — | 2022-01-13 |
| A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis SuppurativaNCT03607487results2020-09-21Number of Treatment-emergent Adverse Events (TEAEs)Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: INCB054707, Placebo | Hidradenitis Suppurativa | 35 | 2019-08-13actual | — | 2025-08-21 |
| Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)NCT02252159observationalDescription of patterns of the disease Polycythemia Vera (PV), and associations of such patterns with patients' exposures or treatments | — | Completed | — | MPN (Myeloproliferative Neoplasms) | 2,544 | 2019-08-03actual | — | 2021-04-26 |
| GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host DiseaseNCT03139604results2020-05-15Overall Response Rate Based on Center for International Blood and Marrow Transplant Research (CIBMTR) Response IndexRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Itacitinib, Placebo, Prednisone, Methylprednisolone | Graft-versus-host Disease (GVHD) | 439 | 2019-05-02actual | — | 2025-09-02 |
| A Study of the Safety of INCB054707 in Participants With Hidradenitis SuppurativaNCT03569371results2020-05-20Number of Participants With Treatment-emergent Adverse Events (TEAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: INCB054707 | Hidradenitis Suppurativa | 10 | 2019-04-22actual | — | 2022-09-26 |
| A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid TumorsNCT03361228results2020-05-21Phase 1 Only: Safety and Tolerability of INCB001158 in Combination With Epacadostat ± Pembrolizumab as Assessed by Number of Participants With a Treatment-emergent Adverse Event (TEAE)Non-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Study was terminated early based on emerging data with epacadostat and pembrolizumab. | Drug: INCB001158, Epacadostat, Pembrolizumab | Solid Tumors | 5 | 2019-03-30actual | — | 2020-05-21 |
| An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced MalignanciesNCT02265510results2020-04-17Phase 1a and 1b: Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminated | Drug: INCB052793, gemcitabine, nab-paclitaxel, dexamethasone, Carfilzomib, bortezomib, lenalidomide, azacitidine, INCB052793, pomalidomide, INCB050465, INCB039110 | Solid Tumors, Advanced Malignancies, Metastatic Cancer | 83 | 2019-02-27actual | — | 2020-04-17 |
| A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)NCT02998476results2020-04-24Objective Response Rate Based on Lugano Classification Criteria in Group ANon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Parsaclisib | Lymphoma | 60 | 2019-02-22actual | — | 2025-08-22 |
| Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)NCT02959437results2020-03-05Part 1 and 2 : Number of Participants With Treatment Emergent Adverse EventsNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Study terminated by Sponsor | Drug: Azacitidine, Pembrolizumab, Epacadostat, INCB057643, Pembrolizumab, Epacadostat, INCB059872 | Solid Tumors, Advanced Malignancies, Metastatic Cancer | 70 | 2019-02-15actual | — | 2025-10-21 |
| Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesNCT02711137results2022-04-28Number of Participants With Treatment Emergent Adverse Events (TEAE's).Non-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Study terminated due to safety issues. | Drug: INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine | Solid Tumors | 137 | 2019-02-13actual | — | 2025-10-21 |
| A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)NCT03085914results2020-05-07Phases 1 & 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEsNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: Epacadostat, Pembrolizumab, Oxaliplatin, Leucovorin, 5-Fluorouracil, Gemcitabine, nab-Paclitaxel, Carboplatin, Paclitaxel, Pemetrexed, Cyclophosphamide, Carboplatin, Cisplatin, 5-Fluorouracil, Investigator's choice of platinum agent | Solid Tumor | 70 | 2019-01-25actual | — | 2022-09-23 |
| Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)NCT03322540results2020-02-05Objective Response Rate (ORR) of Pembrolizumab Plus Epacadostat Versus Pembrolizumab Plus PlaceboRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Pembrolizumab, Epacadostat, Placebo | Lung Cancer | 154 | 2019-01-10actual | — | 2025-08-22 |
| Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)NCT01348490results2020-01-28Percent Change From Baseline in Spleen Volume at Week 24 by Final Titrated DoseOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Ruxolitinib | MPN (Myeloproliferative Neoplasms) | 66 | 2018-12-19actual | — | 2020-01-28 |
| A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)NCT03322566results2020-01-29Objective Response Rate (ORR) of Pembrolizumab + Chemotherapy + Epacadostat Versus Pembrolizumab + Chemotherapy + PlaceboRandomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Pembrolizumab, Epacadostat, Platinum-based chemotherapy, Placebo | Lung Cancer | 233 | 2018-12-13actual | — | 2022-01-24 |
| Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected CancersNCT02178722results2019-12-19Phase 1: Percentage of Participants With Treatment-Emergent Adverse Events (TEAE) and Serious Treatment-Emergent Adverse EventsNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: MK-3475, INCB024360 | Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC), Gastric Cancer, Lung Cancer, Lymphoma, Renal Cell Carcinoma (RCC), Ovarian Cancer, Solid Tumors, UC (Urothelial Cancer), Melanoma, Bladder Cancer, Triple Negative Breast Cancer (TNBC) | 444 | 2018-11-26actual | — | 2022-02-14 |
| A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell DiseaseNCT03132324Safety and tolerability of INCB059872 assessed by monitoring frequency, duration, and severity of adverse eventsNon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: This study is terminated due to a business decision not to pursue INCB059782 in Sickle Cell Disease indication. | Drug: INCB059872 | Sickle Cell Disease | 12 | 2018-10-03actual | — | 2019-10-28 |
| A Study of INCB018424 Phosphate Cream in Subjects With VitiligoNCT03099304results2021-12-10Percentage of Participants Treated With Ruxolitinib Cream Who Achieved a ≥ 50% Improvement From Baseline in Facial Assessment of the Vitiligo Area and Severity Index Score (F-VASI50) Compared With Participants Treated With Vehicle at Week 24Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Ruxolitinib cream, Vehicle cream | Vitiligo | 157 | 2018-09-12actual | — | 2022-11-17 |
| Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid TumorsNCT02559492Number of Participants With Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Terminated | Drug: Itacitinib, Epacadostat, Itacitinib, INCB050465 | Solid Tumors | 142 | 2018-09-10actual | — | 2019-09-25 |
| Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)NCT03260894results2019-09-10Objective Response Rate (ORR) of Pembrolizumab + Epacadostat Versus Standard of Care (SOC)Randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Pembrolizumab, Epacadostat, Sunitinib, Pazopanib | Renal Cell Carcinoma (RCC) | 129 | 2018-08-22actual | — | 2026-05-22 |
| Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)NCT03361865results2019-08-29Objective Response Rate (ORR) With Pembrolizumab + Epacadostat Versus Pembrolizumab + PlaceboRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Pembrolizumab, Epacadostat, Placebo | UC (Urothelial Cancer) | 93 | 2018-08-09actual | — | 2025-08-22 |
| Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial CarcinomaNCT03374488results2019-08-28Objective Response Rate (ORR) With Pembrolizumab + Epacadostat Versus Pembrolizumab + PlaceboRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Pembrolizumab, Epacadostat, Placebo | UC (Urothelial Cancer) | 84 | 2018-07-27actual | — | 2025-08-22 |
| Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)NCT03358472results2019-09-10Objective Response Rate (ORR) of Pembrolizumab + Epacadostat, Pembrolizumab Monotherapy and the EXTREME RegimenRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Pembrolizumab, Epacadostat, Cetuximab, Cisplatin, Carboplatin, 5-Fluorouracil | Head and Neck Cancer | 89 | 2018-07-19actual | — | 2025-12-03 |
| Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung CancerNCT03348904results2019-06-13Overall Survival (OS) of Nivolumab Plus Epacadostat in Combination With Chemotherapy (Arm A) Compared to Chemotherapy (Arm B)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ | Phase 3 | Terminatedsponsor's stated reason: Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention. | Drug: Nivolumab, Epacadostat, Placebo, Carboplatin, Cisplatin, Gemcitabine, Paclitaxel, Pemetrexed | Lung Cancer | 2 | 2018-05-22actual | — | 2019-06-13 |
| Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)NCT03342352Progression-free survival (PFS) with nivolumab plus epacadostat in combination with chemotherapy (Arm A) compared to the EXTREME regimen (Arm B)Randomized · Quadruple-masked · Treatment | Phase 3 | Withdrawnsponsor's stated reason: Study was cancelled prior to enrolling any patients. | Drug: Nivolumab, Epacadostat, Placebo, Carboplatin, Cisplatin, Cetuximab, 5-Fluorouracil | Head and Neck Cancer | 0 | 2018-04-20actual | — | 2019-12-20 |
| An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced MalignanciesNCT02431260results2019-06-14Number of Participants With a Treatment-emergent Adverse Event (TEAE)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: As of 31 JAN 2018, the study was terminated by the sponsor due to PK variability. | Drug: INCB054329 Monotherapy | Solid Tumors and Hematologic Malignancy | 69 | 2018-01-31actual | — | 2019-06-14 |
| A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)NCT02953678results2019-08-20Overall Response Rate (ORR) at Day 28Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Ruxolitinib, Prednisone or methylprednisolone | Graft-versus-host Disease (GVHD) | 71 | 2018-01-31actual | — | 2021-11-24 |
| A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic DermatitisNCT03011892results2021-04-09Mean Percentage Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 4 in Participants Treated With Ruxolitinib 1.5% Cream Twice a Day (BID) Compared With Participants Treated With Vehicle Cream BIDRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Ruxolitinib 0.15% Cream QD, Ruxolitinib 0.5% Cream QD, Ruxolitinib 1.5% Cream QD, Ruxolitinib 1.5% Cream BID, Triamcinolone 0.1% Cream BID, Vehicle Cream BID | Atopic Dermatitis | 307 | 2018-01-10actual | — | 2021-04-09 |
| A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)NCT02752074results2019-05-15Progression-free SurvivalRandomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: pembrolizumab + epacadostat, pembrolizumab + placebo | Melanoma | 706 | 2018-01-08actual | — | 2025-08-24 |
| A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial CarcinomaNCT02298153Incidence of adverse events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention. | Drug: Epacadostat, Atezolizumab | NSCLC (Non-small Cell Lung Carcinoma), UC (Urothelial Cancer) | 29 | 2017-11-08actual | — | 2026-04-20 |
| A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)NCT02553330results2020-12-16Part A: Percentage of Participants Achieving a ≥ 50% Improvement in SALT50 Response in Terminal Hair (Pigmented and Nonpigmented).Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: The study was terminated early based on the results of a planned interim analysis. | Drug: Placebo Cream, Ruxolitinib Phosphate Cream | Alopecia Areata | 90 | 2017-10-03actual | — | 2020-12-16 |
| A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic MelanomaNCT01604889Phase 1: Number of patients with adverse events as a measure of Safety and Tolerability.Randomized · Quadruple-masked · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Further development of this compound with ipilimumab in the treatment of melanoma is no longer being pursued. | Drug: Epacadostat, ipilimumab | Melanoma | 50 | 2016-12-27actual | — | 2026-04-21 |
| INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin LymphomaNCT02456675Objective Response Rate (ORR) as determined by the percentage of subjects achieving a partial response (PR) or complete response (CR)Non-randomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: A decision was made to terminate the study due to the changing treatment landscape for the development of new agents in combination in Hodgkin lymphoma. | Drug: INCB040093 Monotherapy, INCB040093, itacitinib | Refractory Hodgkin Lymphoma, Recurrent Adult Hodgkin's Lymphoma | 8 | 2016-12-16actual | — | 2018-01-12 |
| Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHDNCT02614612Assess safety and tolerability of study treatment as measured by the frequency and severity of adverse events and serious adverse eventsRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Itacitinib (200 mg), Itacitinib (300 mg), prednisone or methylprednisolone (corticosteroids) | Graft-versus-host Disease (GVHD) | 31 | Jun 2016actual | — | 2019-03-08 |
| Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid TumorsNCT01858883Safety and tolerability of combination therapy study treatment itacitinib (INCB039110) plus nab-paclitaxel and gemcitabine as measured by the number of participants with adverse eventsOpen-label · Treatment | Phase 1/2 | Completed | Drug: itacitinib, Gemcitabine, nab-paclitaxel, filgrastim | Solid Tumors, Pancreatic Cancer | 55 | Feb 2016actual | — | 2019-07-18 |
| Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)NCT02117479results2017-07-11Overall Survival (OS)Randomized · Double-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: The study was terminated early based on the results of the planned interim analysis. | Drug: Ruxolitinib, Placebo, Capecitabine | Pancreatic Cancer | 321 | Feb 2016actual | — | 2019-03-26 |
| A Study of Ruxolitinib in Pancreatic Cancer PatientsNCT02119663results2017-06-06Overall Survival (OS)Randomized · Double-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: The safety committee found no safety issues but recommended halting the study based on a lack of efficacy in a similar trial. The sponsor terminated the trial. | Drug: Ruxolitinib, Placebo, Capecitabine | Pancreatic Cancer | 86 | Feb 2016actual | — | 2018-02-13 |
| Study of Ruxolitinib in Colorectal Cancer PatientsNCT02119676results2017-06-14Overall Survival (OS)Randomized · Double-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Substudy 1 was terminated for futility at interim analysis and Substudy 2 was terminated per sponsor decision. | Drug: Ruxolitinib, Regorafenib, Placebo | CRC (Colorectal Cancer) | 396 | Feb 2016actual | — | 2018-02-13 |
| A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast CancerNCT02120417results2017-07-12Overall Survival (OS)Randomized · Double-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: The study was terminated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation. | Drug: Ruxolitinib, Capecitabine, Placebo | Breast Cancer | 149 | Feb 2016actual | — | 2018-02-13 |
| Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung CancerNCT02257619Number of Participants With Dose Limiting Toxicities (DLTs)Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision to not initiate part 2 due to slow enrollment and competing trials. | Drug: Itacitinib, docetaxel | NSCLC (Non-small Cell Lung Carcinoma) | 9 | Feb 2016actual | — | 2026-04-21 |
| Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung CancerNCT02119650results2017-06-14Overall Survival (OS)Randomized · Double-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: The study was terminated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation. | Drug: Ruxolitinib, Placebo, Pemetrexed, Cisplatin | NSCLC (Non-small Cell Lung Carcinoma) | 76 | 2016-02-11actual | — | 2018-02-13 |
| An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid TumorsNCT01822756results2017-04-13Percentage of Participants With Adverse Events That Are Defined as Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Dose escalation ended after Cohort B1, RUX 10 mg BID - GCSF in October 2014. | Drug: ruxolitinib, gemcitabine, nab-paclitaxel, filgrastim | Solid Tumors, Pancreatic Cancer | 42 | Sep 2015actual | — | 2018-02-12 |
| Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating MutationsNCT02355431Part 1: Determination of the dose of itacitinib that is safe and tolerable in combination with erlotinib as measured by the number of dose-limiting toxicities (DLTs) observed in the evaluation cohort.Randomized · Quadruple-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Study withdrawn before enrolling first patient | Drug: Itacitinib, erlotinib, placebo | Solid Tumors and Hematologic Malignancy, NSCLC (Non-small Cell Lung Carcinoma) | 0 | Sep 2015actual | — | 2019-03-08 |
| A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line ChemotherapyNCT01685255Progression free survival (PFS) using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 definition of progression as determined by the investigator.Randomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Study was terminated by the sponsor for lack of evidence of superiority and slow study accrual. | Drug: Epacadostat, tamoxifen | Ovarian Cancer, Genitourinary (GU) Tumors | 83 | 2014-10-23actual | — | 2019-03-11 |
| Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)NCT02093429Proportion of subjects who achieve a response for Hematologic Improvement in Erythrocytes (HI-E) during any 8-week period within the first 16-week treatment period with INCB047986 Monotherapy.Randomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Business decision. | Drug: INCB047986 | MDS (Myelodysplastic Syndrome) | 6 | Sep 2014actual | — | 2018-01-17 |
| An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced MalignanciesNCT01929941Adverse events that are defined as dose limiting toxicities occurring in the first 21 days of treatment in Group 1 and the first 28 days of treatment in Group 2.Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Business decision. | Drug: INCB047986, INCB047986, Gemcitabine, nab-paclitaxel | Solid Tumor, Hodgkin's Lymphoma, NHL (Non-Hodgkin Lymphoma), Pancreatic Cancer, Breast Cancer, UC (Ureter and Urethera), Advanced Cancer, Metastatic Cancer | 5 | Aug 2014actual | — | 2018-01-17 |
| INCB047986 in Rheumatoid ArthritisNCT02151474Percentage of participants with adverse events, changes in electrocardiograms (ECGs), vital signs, physical examinations, or clinical laboratory evaluationsRandomized · Double-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Business decision. | Drug: INCB047986, Placebo | Rheumatoid Arthritis | 3 | Aug 2014actual | — | 2015-02-23 |
| Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief StudyNCT01632904results2015-04-07Percentage of Subjects Achieving a ≥ 50% Improvement From Baseline in Total Symptom Score-Cytokine (TSS-C) at Week 16, as Measured by the Modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) DiaryRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Ruxolitinib, Hydroxyurea (HU), HU-placebo, Ruxolitinib-placebo | Polycythemia Vera | 110 | Mar 2014actual | — | 2017-11-14 |
| Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)NCT01243944results2015-03-06The Percentage of Participants Achieving a Primary Response at Week 32Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: ruxolitinib tablets · Other: Best Available Therapy (BAT) | Polycythemia Vera | 222 | 2014-01-15actual | — | 2019-03-06 |
| An Open Label Study of Itacitinib Administered Orally in Patients With MyelofibrosisNCT01633372Proportion of subjects with >/= 50% reduction in total symptom score in each dose group, as measured by the modified The Myelofibrosis Symptom Assessment Form (MFSAF) v3.0 diaryRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: itacitinib | MPN (Myeloproliferative Neoplasms) | 87 | 2013-12-31actual | — | 2021-08-30 |
| A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid ArthritisNCT01626573Safety and tolerability of itacitinib as assessed by the changes in frequency and severity of adverse events, ECGs, vital signs, physical examinations, and clinical laboratory evaluations.Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Itacitinib, Itacitinib Placebo | Rheumatoid Arthritis | 106 | Jul 2013actual | — | 2019-03-12 |
| Study of Ruxolitinib in Pancreatic Cancer PatientsNCT01423604results2016-08-29Overall SurvivalRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Capecitabine, Ruxolitinib, Placebo | Pancreatic Cancer | 136 | Jun 2013actual | — | 2018-02-12 |
| A Dose-escalation Study in Subjects With Advanced MalignanciesNCT01195311Safety and tolerability as measured by adverse events and dose limiting toxicitiesOpen-label · Treatment | Phase 1 | Completed | Drug: INCB024360 | Solid Tumors and Hematologic Malignancy | 52 | May 2013actual | — | 2018-01-17 |
| Alternative Dosing Strategy of Ruxolitinib in Patients With MyelofibrosisNCT01445769results2014-09-19Mean Percentage Change From Baseline in Spleen Volume at Week 24Open-label · Treatment | Phase 2 | Completed | Drug: Ruxolitinib | Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis | 45 | Mar 2013actual | — | 2019-03-27 |
| A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque PsoriasisNCT01634087Safety and tolerability of itacitinib as measured by changes in frequency and severity of adverse events, ECGs, physical examination, vital signs, and clinical laboratory evaluations.Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Itacitinib, Placebo | Plaque Psoriasis | 50 | Jan 2013actual | — | 2019-03-12 |
| A Dose-escalation Study in Subjects With Advanced MalignanciesNCT01072266Safety and tolerability will be the primary endpoint and will be assessed by monitoring the frequency, duration, and severity of AEsOpen-label · Treatment | Phase 1 | Completed | Drug: INCB028060 | Solid Tumor, Advanced Cancer, Metastatic Cancer | 45 | Jul 2012actual | — | 2017-11-22 |
| Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis PatientsNCT01340651results2013-09-25Percentage of Participants With at Least 1 Adverse Event From Baseline Through Week 16Open-label · Treatment | Phase 2 | Completed | Drug: Ruxolitinib | Myelofibrosis | 41 | Jul 2012actual | — | 2014-03-10 |
| Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast CancerNCT01254136Evaluation of safety and tolerabilty as determined by monitoring the frequency and severity of adverse events (AEs) and performing clinical assessments and laboratory investigations.Non-randomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Incyte has suspended development of the compound. | Drug: INCB007839 300mg BID, Trastuzumab, Vinorelbine | Breast Cancer | 20 | Sep 2011actual | — | 2012-01-25 |
| Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast CancerNCT00864175Overall response rate (complete + partial response) using RECIST (Response Evaluation Criteria in Solid Tumor) criteriaNon-randomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Incyte suspended development of the compound. | Drug: INCB007839, INCB007839, INCB007839, INCB007839, trastuzumab, Docetaxel | Breast Cancer | 68 | Jun 2011actual | — | 2018-01-18 |
| COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I TrialNCT00952289results2012-01-24Number of Participants Achieving ≥ 35% Reduction in Spleen Volume From Baseline to Week 24Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Ruxolitinib, Placebo | MPN (Myeloproliferative Neoplasms) | 309 | Nov 2010actual | — | 2018-03-12 |
| A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple MyelomaNCT00639002results2012-01-23Number of Responders According to the International Uniform Response Criteria for Multiple MyelomaOpen-label · Treatment | Phase 2 | Completed | Drug: Ruxolitinib 25 mg, Dexamethasone 40 mg | Multiple Myeloma | 13 | Jul 2010actual | — | 2018-02-13 |
| INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic DrugsNCT00902486results2018-09-04The Percentage of Participants Achieving American College of Rheumatology (ACR) 20 ImprovementRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: INCB028050, INCB028050, INCB028050, Placebo | Rheumatoid Arthritis | 127 | Jun 2010actual | — | 2018-09-04 |
| Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential ThrombocythemiaNCT00726232results2012-02-24Percentage of Polycythemia Vera Participants With a Confirmed Clinical Partial Response (PR) or Complete Response (CR)Randomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Termination of the clinical trial by sponsor. | Drug: Ruxolitinib | Myeloproliferative Neoplasm (MPN) | 73 | 2010-06-20actual | — | 2025-10-29 |
| A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque PsoriasisNCT00778700results2022-02-09Absolute Change From Baseline in Total Lesion Score for All Treatable Psoriatic Lesions to Day 84Randomized · Double-masked · Treatment | Phase 2 | Completed | Other: Placebo Cream · Drug: Ruxolitinib Phosphate | Psoriasis | 199 | 2009-06-26actual | — | 2022-02-09 |
| Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With PsoriasisNCT00617994results2022-02-08Number of Treatment of Emergent Adverse EventsNon-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: Ruxolitinib | Psoriasis | 25 | 2009-04-30actual | — | 2022-02-08 |
| Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 DiabeticsNCT00698230Change from Baseline to Week 12 in hemoglobin A1c (HbA1c)Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: INCB013739, INCB013739, INCB013739, INCB013739, INCB013739, Placebo comparator matching INCB013739, Metformin | Type 2 Diabetes | 302 | Apr 2009actual | — | 2018-02-14 |
| Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 DiabetesNCT00698789Safety and tolerability as determined by monitoring of AEs, vital signs, ECGs, physical examinations, and clinical laboratory blood and urine parameters.Randomized · Double-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Study ended after diabetes development plan review. . | Drug: INCB019602, INCB019602, INCB019602, INCB019602, INCB019602, Placebo, Metformin | Type 2 Diabetes | 48 | Feb 2009actual | — | 2012-10-30 |
| Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate CancerNCT00638378results2012-01-20Number of Participants With a Prostate-specific Antigen ResponseOpen-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: According to the protocol, the sponsor terminated the study after it was determined that less than 2 of the first 22 patients showed a PSA50 response. | Drug: Ruxolitinib | Prostate Cancer | 22 | Jan 2009actual | — | 2018-02-12 |
| Open-Label Study to Assess the Safety/Tolerability in Patients With Solid TumorsNCT00820560Identify a maximum tolerable dose as measured through adverse event reporting, ECGs and laboratory assessmentsRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: INCB007839 | Solid Tumors and Hematologic Malignancy | 41 | Jan 2009actual | — | 2018-01-17 |
| A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque PsoriasisNCT00820950results2022-02-08Change in Target Lesion Individual Component Scores for Erythema, Scaling and Thickness Compared to BaselineRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Ruxolitinib phosphate cream, Dovonex® calcipotriene 0.005%, Diprolene® AF betamethasone dipropionate 0.05% cream., Placebo cream, Ruxolitinib phosphate cream, Ruxolitinib phosphate cream | Psoriasis | 29 | 2009-01-31actual | — | 2022-02-08 |
| A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid ArthritisNCT00550043results2015-03-23The Percentage of Subjects Achieving American College of Rheumatology (ACR) 20 ImprovementRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: INCB018424, Placebo | Rheumatoid Arthritis | 50 | Sep 2008actual | — | 2015-03-23 |
| Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia MyelofibrosisNCT00509899results2012-08-02Number of Participants With Adverse Events (AEs)Open-label · Treatment | Phase 1/2 | Completed | Drug: Ruxolitinib | Myelofibrosis, Polycythemia Vera, Thrombocytosis | 154 | Dec 2007actual | — | 2018-03-12 |
| Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic SubjectsNCT00478322Changes in lipid profile laboratory valuesRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Placebo, INCB013739 | Diabetes Mellitus, Type 2, Obesity | 24 | Nov 2007actual | — | 2016-12-06 |
| Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected PatientsNCT00393120Safety and tolerability will be assessed by monitoring adverse experiences.Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: INCB009471, INCB009471, Placebo comparator | HIV Infections | 45 | Sep 2007actual | — | 2018-03-26 |
| A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to DiabetesNCT00398619Assessment of pharmacokinetics of INCB013739 through analysis of blood samples.Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: INCB13739 | Insulin Resistance, Obesity | — | Mar 2007actual | — | 2012-01-23 |
| Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIsNCT00300573Percent of subjects with >= 1.0 log10 decrease in viral load from Baseline to Week 24 based on non-completer equals failure (NC=F)Randomized · Quadruple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Development program ended due to inability to pair with other cytidine analogs and higher risk of hyperlipasemia when not used with 3TC/FTC. | Drug: Dexelvucitabine | HIV Infections, Human Immunodeficiency Virus | 250 | — | — | 2018-08-23 |
| An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell TransplantNCT03147742expanded access | — | Approved for marketing | Drug: Ruxolitinib | Graft-versus-host Disease (GVHD) | — | — | — | 2022-06-07 |
| Expanded Access Use of INCB054329 to Treat a Single Patient With Metastatic Renal Cell CarcinomaNCT03896815expanded access | — | No longer available | Drug: INCB054329 | — | — | — | — | 2019-04-01 |
| Expanded Access Use of Itacitinib to Treat a Single Patient With Aplastic AnemiaNCT03906318expanded access | — | No longer available | Drug: Iticitinib | Aplastic Anemia | — | — | — | 2022-09-30 |
| Expanded Access Use of INCB052793 to Treat a Single Patient With MyelofibrosisNCT03906344expanded access | — | No longer available | Drug: INCB052793 | — | — | — | — | 2019-04-08 |
| Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic CancerNCT03906357expanded access | — | No longer available | Drug: Pemigatinib | — | — | — | — | 2022-04-19 |
| Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 InfectionNCT04355793expanded access | — | No longer available | Drug: Ruxolitinib | COVID-19 | — | — | — | 2021-12-15 |
| Expanded Access of Axatilimab to Treat a Single Patient With Chronic Graft Versus Host Disease (GVHD)NCT05544032expanded access | — | Approved for marketing | Drug: axatilimab | Chronic Graft Vs. Host Disease | — | — | — | 2026-07-10 |
| Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) DiseaseNCT05561985expanded access | — | Available | Drug: Itacitinib | STAT1 Gain-of-Function Disease | — | — | — | 2026-06-10 |
| Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHDNCT05722912expanded access | — | Approved for marketing | Drug: Ruxolitinib | Graft-versus-host Disease (GVHD) | — | — | — | 2023-02-10 |
| An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)NCT06910137expanded access | — | Available | Drug: retifanlimab | Squamous Cell Carcinoma of the Anal Canal | — | — | — | 2026-01-08 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19